New antibody drug aims to control kidney disease
NCT ID NCT07375758
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called MIL116 in healthy volunteers and people with IgA nephropathy, a kidney disease. The drug is given as a shot under the skin and aims to reduce harmful antibodies that damage the kidneys. The study checks for safety, side effects, and how well the drug works over several weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOGLOBULIN A NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
RECRUITINGBeijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to slow kidney failure in common kidney disease
- New drug aims to plug kidney leaks in multiple diseases
- New drug shows promise for kidney disease patients
- New antibody VIS649 tested in humans for first time to fight kidney disease
- New drug shows promise for slowing kidney disease in IgA nephropathy patients
- New drug shows promise for kidney disease in phase 2 trial